Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Paraproteinemias 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia 1Kidney Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 22Nivolumab 14enfortumab vedotin 13Gemcitabine 11Specimen Handling 9Magnetic Resonance Spectroscopy 9Cisplatin 8Carboplatin 8sacituzumab govitecan 6avelumab 6Docetaxel 6atezolizumab 5Ipilimumab 5durvalumab 4Paclitaxel 4cabozantinib 3Taxes 3Mitomycin 3CTLA-4 Antigen 3tislelizumab 2relatlimab 2erdafitinib 2disitamab vedotin 2Radiosurgery 2Platinum 2Oxaliplatin 2Immunoglobulin G 2Fluorouracil 2Disulfides 2ALT-803 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × Blood Cell Count × 90 days × Clear all
NCT07485114 2026-03-20

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Tel-Aviv Sourasky Medical Center

Recruiting
300 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡